NYUAD study finds protein aggregation inhibitor can be used to develop cancer therapies

(New York University) A new study provides important insights into the p53 protein, a critical tumor suppressor often mutated and deactivated in cancer, and a key target in the development of cancer therapeutics. Using protein mimetics (small molecules that mimic proteins) originally designed to prevent aggregation of proteins associated with Alzheimer's disease and type II diabetes, the researchers were able to breakdown p53 aggregates and reactivate the protein, leading to the death of cancer cells.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news